SCHEMBL16771129

SCHEMBL16771129

NC(=O)c1cc(C2CC2)c(CN2CCC(Oc3ccc(Cl)cc3Cl)CC2)cc1F

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 9/20 0.52
▸ HRH1 P35367 1/20 0.45
▸ CCR3 P51677 1/20 0.45
▸ SCN7A Q01118 2/20 0.41
▸ SCN5A Q14524 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ SCN1A P35498 2/20 0.40
▸ SCN8A Q9UQD0 2/20 0.40
▸ SCN4A P35499 1/20 0.39
▸ SCN2A Q99250 1/20 0.39
▸ SCN3A Q9NY46 1/20 0.39
▸ EGFR P00533 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ KCNH2 Q12809 1/20 0.38
▸ UTS2R Q9UKP6 1/20 0.38
▸ EPHX2 P34913 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16771001 0.93 SCN9A (0.50) SCN9AHRH1CCR3SCN7ASCN5A
SCHEMBL23159341 0.92 SCN9A (0.51) SCN9AHRH1CCR3SCN7ASCN5A
SCHEMBL16771148 0.92 HRH1 (0.47) SCN9AHRH1CCR3SCN7ASCN5A
Hydrochloric Acid SCHEMBL16758883 0.91 HRH1 (0.47) SCN9AHRH1CCR3SCN7ASCN5A
SCHEMBL16771185 0.88 SCN9A (0.58) SCN9AHRH1CCR3SCN7ASCN5A
SCHEMBL16758989 0.87 HRH1 (0.42) SCN9AHRH1CCR3SCN7ASCN5A
SCHEMBL18675634 0.86 SCN9A (0.56) SCN9AHRH1CCR3KCNH2
SCHEMBL17069407 0.85 SCN9A (0.48) SCN9ASCN7ASCN5ASCN1ASCN8A
SCHEMBL17062087 0.85 SCN7A (0.60) SCN9ASCN7ASCN5ASCN1ASCN8A
SCHEMBL17061954 0.85 SCN9A (0.61) SCN9ASCN7ASCN5ASCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2021-04-01 — — US disclosed
US-9694002-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-07-04 — — US disclosed
US-9694002-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-07-04 — — US disclosed
US-20170087136-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-03-30 — — US disclosed
US-20170087136-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2017-03-30 — — US disclosed
US-9546164-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-01-17 — — US disclosed
US-9546164-B2 Substituted benzamides and methods of use thereof GENENTECH, INC. (US) 2017-01-17 — — US disclosed
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2015-09-10 — — US disclosed
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF XENON PHARMACEUTICALS INC. (CA) 2015-09-10 — — US disclosed
WO-2015078374-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2015-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210093618-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, SULT2A1 SCN9A 1605/4885HRH1 159/4885CCR3 2229/4885
US-20150252038-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF BRIX1, RDX, RRM1 SCN9A 1669/4885HRH1 134/4885CCR3 2039/4885
US-20170087136-A1 SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF C1R, SRR, PNISR SCN9A 505/4885HRH1 670/4885CCR3 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback